Kinnevik AB publ Has $71.07 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Kinnevik AB publ grew its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 12.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,434,171 shares of the company's stock after buying an additional 1,528,503 shares during the period. Recursion Pharmaceuticals accounts for about 100.0% of Kinnevik AB publ's portfolio, making the stock its biggest holding. Kinnevik AB publ owned approximately 3.34% of Recursion Pharmaceuticals worth $71,067,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Ensign Peak Advisors Inc raised its holdings in Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock valued at $2,774,000 after acquiring an additional 1,300 shares during the period. Farther Finance Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in shares of Recursion Pharmaceuticals by 7.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after purchasing an additional 1,875 shares during the period. Clear Creek Financial Management LLC increased its stake in shares of Recursion Pharmaceuticals by 9.8% during the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after purchasing an additional 1,907 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded up $0.05 during midday trading on Thursday, hitting $5.26. The stock had a trading volume of 16,582,108 shares, compared to its average volume of 15,972,568. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The company's 50-day moving average price is $4.86 and its 200-day moving average price is $6.14. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Morgan Stanley started coverage on Recursion Pharmaceuticals in a report on Thursday. They issued an "equal weight" rating and a $5.00 price objective on the stock. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.